A case of mistaken MELD (model for end stage liver disease) score-How an acute hemolytic transfusion reaction falsely altered a patient's transplant status.
RBC transfusion
blood management
transfusion practices (adult)
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
09
01
2023
received:
06
04
2022
accepted:
09
01
2023
medline:
12
4
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
An acute hemolytic transfusion reaction (AHTR) caused by intravascular hemolysis features a decrease in hemoglobin/hematocrit, reduced haptoglobin, and increases in creatinine, and bilirubin. Acute intravascular hemolysis carries its own morbidity and mortality, especially in the setting of a patient liver disease related pre-existing alterations in hemostasis. Additionally, AHTR significantly impacts the laboratory values used in calculating the Model for End Stage Liver Disease (MELD) score and thus liver transplant status. Herein, we present a case of a patient with hepatorenal syndrome due to ESLD on the transplant list who developed an AHTR due to an evolving anti-Jka that initially presented as non-specific reactivity in solid phase adherence testing. This evolving antibody caused intravascular hemolysis and a significant increase in bilirubin from 4.7 to 17.1 mg/dl, thus, raising the MELD score, increasing the predicted short-term mortality risk, and affecting the patient's transplant status. Acute hemolysis caused significant elevation of bilirubin raising the MELD score which increased both the predicted mortality to 70 percent and the perceived urgency of transplant. The MELD score improved after resolution of the AHTR and clearing of the offending Jka-positive RBCs. This case highlights the effect of AHTR on parameters used in the determination of MELD score which significantly increases the perceived short-term mortality and urgency of liver transplant. Therefore, any nonspecific reactivity in initial workup could be due to developing antibodies, and put the patient at higher risk for an acute hemolytic transfusion reaction.
Sections du résumé
BACKGROUND
An acute hemolytic transfusion reaction (AHTR) caused by intravascular hemolysis features a decrease in hemoglobin/hematocrit, reduced haptoglobin, and increases in creatinine, and bilirubin. Acute intravascular hemolysis carries its own morbidity and mortality, especially in the setting of a patient liver disease related pre-existing alterations in hemostasis. Additionally, AHTR significantly impacts the laboratory values used in calculating the Model for End Stage Liver Disease (MELD) score and thus liver transplant status.
CASE REPORT
Herein, we present a case of a patient with hepatorenal syndrome due to ESLD on the transplant list who developed an AHTR due to an evolving anti-Jka that initially presented as non-specific reactivity in solid phase adherence testing. This evolving antibody caused intravascular hemolysis and a significant increase in bilirubin from 4.7 to 17.1 mg/dl, thus, raising the MELD score, increasing the predicted short-term mortality risk, and affecting the patient's transplant status.
RESULTS
Acute hemolysis caused significant elevation of bilirubin raising the MELD score which increased both the predicted mortality to 70 percent and the perceived urgency of transplant. The MELD score improved after resolution of the AHTR and clearing of the offending Jka-positive RBCs.
CONCLUSION
This case highlights the effect of AHTR on parameters used in the determination of MELD score which significantly increases the perceived short-term mortality and urgency of liver transplant. Therefore, any nonspecific reactivity in initial workup could be due to developing antibodies, and put the patient at higher risk for an acute hemolytic transfusion reaction.
Substances chimiques
Bilirubin
RFM9X3LJ49
Antibodies
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-887Informations de copyright
© 2023 AABB.
Références
National Healthcare Safety Network. 2021. Accessed January 12, 2022. www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf
Strobel E et al. Hemolytic transfusion reactions. Transfus Med Hemother. 2008;35(5):346-53.
Cohn CS, Delaney M, Johnson ST, et al., editors. Technical manual. 20th ed. Bethesda, MD: AABB Press; 2020.
Yates J, Howell P, Overfield J, Voak D, Downie DM, Austin EB. IgG anti-Jka/Jkb antibodies are unlikely to fix complement. Transfus Med. 1998;8:133-40.
Hamilton JR. Kidd blood group system: a review. Immunohematology. 2015;31(1):29-35.
Sazama K, DeChristopher PJ, Dodd R, et al. Practice parameter for the recognition, management, and prevention of adverse consequences of blood transfusion. College of American Pathologists. Arch Pathol Lab Med. 2000;124:61-70.
Kamath PR, MELD (Model for end stage liver disease) score, 12 year and older. MD+ Calc. 2001. Accessed February 5, 2022. https://www.mdcalc.com/meld-score-model-end-stage-liver-disease-12-older
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-6.
Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-8.
Organ procurement and transplantation network (OPTN) policies. Accessed March 23, 2022. https://optn.transplant.hrsa.gov/governance/policies/
Lau T, Ahmad J. Clinical applications of the model for end-stage liver disease (MELD) in hepatic medicine. Hepatic Med. 2013;5:1-10.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-70.
Asrani SK, Kim WR. Model for end stage liver disease: end of the first decade. Clin Liver Dis. 2011;15(4):685-98.
Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion. 2002;39:6-10. https://doi.org/10.1046/j.1537-2995.1999.39199116888.x
Leger RM, Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion. 1999;39:11-6. https://doi.org/10.1046/j.1537-2995.1999.39199116889.x
Ziman A, Cohn C, Carey PM, Dunbar NM, Fung MK, Greinacher A, et al. Warm-reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice. Transfusion. 2017;57:463-77. https://doi.org/10.1111/trf.13903